A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil

Keitz, Alexander von; Rajfer, Jacob; Segal, Scott; Murphy, Aileen; Denne, Jonathan; Costigan, Timothy M.; Lockhart, Daniel C.; Beasley, Charles M.; Emmick, Jeffrey T.

doi:10.1016/j.eururo.2003.11.030

Cited by 100 publications

(68 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Patients following sildenafil dosing instructions were offered to upward titration after 4 weeks of treatment. After 12 weeks patients crossed over, followed by a 12-week extension period when patients chose their doubleblind preferred treatment.…”

Section: Resultsmentioning

confidence: 99%

“…28 Nonmedical (lifestyle) factors might shape patients' and partners' attitudes toward ED treatments, including convenience, cost, ease of administration and 'naturalness' in promoting erection. 32 Although several previous studies have focused on determining patient treatment choices, 24,26,33 the reasons surrounding these treatment choices have not been fully explored. The psychological and interpersonal relationship scales was developed to incorporate outcomes, such as time concerns, spontaneity and sexual self-confidence, which are not assessed in existing measures of sexual function.…”

Section: Resultsmentioning

confidence: 99%

“…27 Furthermore, other studies have shown that the sequence in which treatments are given (that is, sildenafil followed by tadalafil or vice versa) does not seem to affect the treatment preference of the patient. 24,25 In a post hoc analysis, 34 baseline characteristics and post-baseline measurements were carried out to identify factors associated with patients' preference. No baseline characteristics were identified that prospectively distinguished patients' preference for tadalafil or sildenafil.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature

2010

View full text Add to dashboard Cite

The increase in the number of safe and effective ED treatments highlights the importance of patients' preference when choosing a therapeutic option. Several studies assessing these preferences are now available in published literature. This article aims to review and discuss the studies on patients' preference and the data concerning the reasons for preference for one PDE-5 inhibitor over another. A PubMed search was conducted for manuscripts published within the last 10 years containing the search items ED, preference, sildenafil, tadalafil or vardenafil. Selected articles were discerningly reviewed and summarized (design, limitations and relevance). The articles selected were peer reviewed publications on patients' preference and ED published in medical literature since 2000. Preference studies that include either two (tadalafil and sildenafil) or three PDE-5 inhibitors (tadalafil, sildenafil and vardenafil), showed that the majority of the patients preferred tadalafil versus either vardenafil or sildenafil. As the treatment of ED has evolved, patients' preference has become an important aspect of ED therapy, 52-65% of patients prefer tadalafil versus 12-20% vardenafil or 8-30% sildenafil. All founded studies have serious limitations, particularly in terms of dosing differences. Preference for tadalafil was mainly because of the longer duration of action that increases patients' freedom in sexual life. There is a consistency in patients' preference for tadalafil over sildenafil or vardenafil across the studies reviewed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature

2010

View full text Add to dashboard Cite

show abstract

“…144 Thus, 73% of 181 ED patients chose to receive tadalafil during the extension period. 144 These studies have the same limitation as the first crossover study, namely, that the comparison should have been between 20 mg tadalafil and 100 mg sildenafil. For instance, in the blinded trial, only 35% of the men had the ability to titrate to 100 mg sildenafil and this may have biased the preference towards tadalafil.…”

Section: Comparative Trialsmentioning

confidence: 99%

Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

Doggrell

2006

Int J Impot Res

View full text Add to dashboard Cite

Erectile dysfunction (ED) affects up to 50% of men between the ages of 40 and 70 years of age. Sildenafil, vardenafil and tadalafil have all been shown to be similarly effective in the treatment of men with ED of vary etiologies, to have similar adverse effects profiles, and to improve quality-oflife by similar amounts. As these phosphodiesterase 5 (PDE5) inhibitors all increase the hypotensive effects of nitrates, they are not suitable for use in patients taking nitrates for the treatment of ischaemic heart disease. All three inhibitors must be used with caution in patients taking a 1 -adrenoceptors antagonists for benign prostatic hyperplasia. Although nonarteritic anterior ischaemic neuropathy has been reported in some users of the PDE5 inhibitors, there is no conclusive evidence that PDE5 inhibitors cause this rare effect. Tadalafil has a longer half-life than sildenafil or vardenafil, and a longer duration of action than sildenafil and vardenafil. Most preference studies have shown tadalafil to be preferred, but there are serious limitations to some of these studies. One approach to treatment is to give each patient a short-and long-acting agent, and for individuals to decide their preference.

show abstract

“…Patients on sildenafil treatment had the option to increase their dose to 100 mg (limited to 35% of patients in each treatment period to reflect dose usage in clinical practice). PAIRS scores for the second treatment period were evaluated (for complete details on the clinical trial, see Von Keitz et al 19 ).…”

Section: Assessment Of Treatment Sensitivitymentioning

confidence: 99%

A 15-item short form of the Psychological and Interpersonal Relationship Scales

2005

View full text Add to dashboard Cite

Erectile dysfunction (ED) is a prevalent condition associated with complex psychological and interpersonal issues. The Psychological and Interpersonal Relationship Scales (PAIRS) is a valid and reliable measure of Sexual Self-Confidence, Spontaneity, and Time Concerns associated with ED and its treatment. This paper describes the development and validation of a 15-item, short form of PAIRS (SF-PAIRS). Domain scores and psychometric properties of SF-PAIRS were assessed using data from the validation studies of the full-length (23-item) PAIRS. Items in the two briefer scales (Spontaneity and Time Concerns) were identified using internal consistency analyses and crossvalidated during two multinational clinical trials and a community sample. The scales in SF-PAIRS showed good internal consistency, convergent and discriminant validity, were stable over a 2-week period, and showed sensitivity to treatment. SF-PAIRS is a valid, brief measure of psychological and interpersonal outcomes associated with ED.

show abstract

A Multicenter, Randomized, Double-Blind, Crossover Study to Evaluate Patient Preference between Tadalafil and Sildenafil

Cited by 100 publications

References 21 publications

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature

Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature

Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

A 15-item short form of the Psychological and Interpersonal Relationship Scales

Contact Info

Product

Resources

About